Utah Neurotrauma Study | Advanced Diffusion MRI & Brain Resilience | Vielight Neuro
Note on Research: The study discussed in this article was a peer-reviewed, double-blind, sham-controlled exploratory investigation published in the Journal of Neurotrauma. While the findings are statistically significant and promising, the authors note that the results should be considered preliminary and hypothesis-generating. Further research, including larger multi-site trials, is warranted to fully establish clinical efficacy for this specific application.
Read the full published study in the Journal of Neurotrauma here: https://journals.sagepub.com/doi/epub/10.1177/08977151251403554
Read the University of Utah’s press release here: https://healthcare.utah.edu/newsroom/news/2026/01/medical-grade-near-infrared-light-therapy-specific-frequencies-shows-promise
For decades, the conversation around American football and brain health has been dominated by a sense of inevitability. We know about the risks of Chronic Traumatic Encephalopathy (CTE). We know that it’s not just the “big hits” (concussions) that matter, but the thousands of “micro-hits” known as Repetitive Head Acceleration Events (RHAE) that accumulate over a season.
Until now, our best defense has been reactive. But what if we could make the brain itself more resilient to the hit before it even happens?
A groundbreaking new study by the University of Utah provides the first evidence that we might be able to. Published this month in the Journal of Neurotrauma—a top-tier, Q1 journal and the official publication of the National and International Neurotrauma Societies—the study offers a rigorous validation of a new approach.
The secret weapon? A specific, medical-grade application of light therapy known as itPBM (intranasal-transcranial photobiomodulation).
The Study by the Numbers
Lead author Dr. Hannah Lindsey and senior author Dr. Elisabeth Wilde recruited 26 active NCAA Division I collegiate football players for this randomized, double-blind, sham-controlled trial.
The players were split into two groups and monitored over a full 16-week season (preseason through regular season).
-
Active PBM Group (n=13): Self-administered the therapy 3 days a week for 20 minutes per session.
-
Sham PBM Group (n=13): Wore an identical device that delivered no therapeutic light.
The Vielight Neuro 3, superseded by the Vielight Neuro 4
The Technology: 40 Hz Gamma and the "Nasal Key"
This study utilized the Vielight Neuro Gamma 3 (superseded by the Neuro Gamma 4), a specialized device designed to deliver itPBM—a combination of intranasal and transcranial photobiomodulation.
The specific technical parameters were crucial to the study’s design:
-
Wavelength: 810 nm (Near-Infrared), chosen for its ability to penetrate deeper into tissue.
-
Pulse Rate: 40 Hz, a frequency associated with gamma brain oscillations.
-
Power Density: 100 mW/cm² for the transcranial LEDs and 25 mW/cm² for the intranasal applicator.
-
Total Dose: A substantial energy delivery of 240 J/cm² per session.
Why the Nose Matters: The device includes an intranasal LED positioned to illuminate the olfactory bulbs and orbitofrontal cortex. This “pincer maneuver”, combining transcranial LEDs on the skull with an intranasal applicato, allows light to reach ventral (underside) brain structures often missed by standard headsets.
To measure the effects, the researchers used advanced diffusion MRI to track two specific biomarkers:
-
Restricted Diffusion Imaging (RDI): A highly sensitive marker for neuroinflammation (immune cell infiltration).
-
Quantitative Anisotropy (QA): A marker for axonal remodeling and structural repair.
The statistical divergence between the two groups was massive.
The sham PBM group showed increases in diffusion imaging (RDI) across white-matter tracts from preseason to postseason. The active PBM group displayed decreases in selected tracts.
The Findings: "Fire vs. Ice" in the Data
1. The Sham Group (No Light): A Brain on Fire
Without protection, the impacts of the season took a heavy toll.
-
RDI (Inflammation): Showed a statistically significant increase (T=3.15, FDR=0.000) with a very large effect size (R²=0.50). This indicates that 50% of the variance in inflammation was driven by the cumulative head impacts over time.
-
QA (Axonal Stress): Similarly increased (T=2.70, FDR=0.000, R²=0.42), suggesting the brain was actively trying to remodel damaged axons.
2. The Active itPBM Group: Neuroprotective Stability
Despite taking the same hits and playing the same game, the treated athletes showed a completely different brain profile.
-
Relative Stability: The Active group showed no significant increases in inflammation or axonal remodeling markers.
-
Signs of Recovery: In some regions, the Active group actually showed statistically significant decreases in RDI (T=0.77, FDR=0.015), suggesting the therapy may have actively facilitated recovery processes during the season.
